Verteporfin · Visudyne

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Age-Related Macular Degeneration

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Visudyne is indicated for the treatment of: adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or; adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
Product first approved 2000EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Age-Related Macular Degeneration
NCT01570608 · The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
2007-03 – 2011-08 · Age Related Macular Degeneration
What this study did
NCT00429962 · University Hospital, Basel, Switzerland
2006-07 – 2008-06 · Choroidal Neovascularization, Age-Related Macular Degeneration
What this study did
NCT00370539 · Shahid Beheshti University of Medical Sciences
2006-09 – 2006-11 · Neovascular Age-Related Macular Degeneration
What this study did
NCT00041483 · Alcon Research
2002-06 – 2005-08 · Macular Degeneration
What this study did
Other / comorbidity
NCT00049959 · QLT Inc.
est. completion 2004-03 · Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome
What this study did
Phase 2/3 (1)
Age-Related Macular Degeneration
NCT00433017 · Novartis
2007-05 – 2009-07 · Macular Degeneration, Choroidal Neovascularization
What this study did
Phase 2 (16)
Age-Related Macular Degeneration
NCT00492284 · QLT Inc.
2007-07 – 2010-05 · Choroidal Neovascularization, Macular Degeneration
What this study did
NCT00527475 · Texas Retina Associates
2007-05 – 2010-01 · Macular Degeneration
What this study did
NCT00390208 · Bay Area Retina Associates
2006-08 – 2009-12 · Age Related Macular Degeneration
What this study did
NCT00729846 · California Retina Consultants
2006-05 – 2009-07 · Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
What this study did
NCT00359164 · University of British Columbia
2006-07 – 2008-08 · Macular Degeneration
What this study did
NCT00696592 · University of Padova
2007-01-31 – 2008-01-31 · Neovascular Age-related Macular Degeneration
What this study did
NCT00457678 · Vitreous -Retina- Macula Consultants of New York
2007-01 – 2007-12-04 · Age Related Macular Degeneration
What this study did
NCT00347399 · Asociación para Evitar la Ceguera en México
2006-03 – 2007-06-30 · Age Related Macular Degeneration
What this study did
NCT00094120 · Genaera Corporation
2004-10 – 2007-02 · Macular Degeneration
What this study did
NCT00426998 · Retinal Consultants Medical Group
started 2006-04 · Choroidal Neovascularization, Macular Degeneration
What this study did
NCT00140803 · Manhattan Eye, Ear & Throat Hospital
2003-10 – 2007-01 · Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT06381154 · Mayo Clinic
2024-12-06 – 2031-03-31 · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT07488988 · Odense University Hospital
2026-10 – 2028-11 · Surgical Scar
What this study did
NCT03033225 · Mayo Clinic
2017-05-31 – 2023-09-20 · Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Neoplasm, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
What this study did
NCT00211445 · Manhattan Eye, Ear & Throat Hospital
2002-07 – 2006-01 · Chronic Central Serous Chorioretinopathy
What this study did
Phase 1/2 (8)
Age-Related Macular Degeneration
NCT00570193 · Mid-Atlantic Retina Consultations, Inc.
2006-12 – 2011-06 · Choroidal Neovascularization, Macular Degeneration
What this study did
Other / comorbidity
NCT06306638 · Roswell Park Cancer Institute
2024-10-01 – 2029-10-01 · Malignant Solid Neoplasm
What this study did
NCT06807359 · SpectraCure AB
2025-01-06 – 2029-01 · Prostate Cancer
What this study did
NCT03067051 · SpectraCure AB
2017-03-21 – 2027-12-31 · Recurrent Prostate Cancer
What this study did
NCT06944249 · Jöri Pünchera
2025-05-08 – 2026-07-31 · Scar Formation
What this study did
NCT04590664 · Emory University
2021-01-15 – 2025-02-13 · Glioblastoma, Recurrent Glioblastoma
What this study did
NCT00007969 · QLT Inc.
started 2000-10 · Melanoma (Skin)
What this study did
NCT01325181 · Jang Won Heo
2009-07 – 2012-09 · Chronic Central Serous Chorioretinopathy
What this study did
Phase 1 (5)
Age-Related Macular Degeneration
NCT00211419 · Manhattan Eye, Ear & Throat Hospital
— · Maculopathy, Age-Related
What this study did
NCT00403442 · Vitreous -Retina- Macula Consultants of New York
started 2006-09 · Macular Degeneration
What this study did
Other / comorbidity
NCT02702700 · Centre Hospitalier Universitaire Vaudois
2016-01 – 2018-08-28 · Pleural Effusion, Malignant
What this study did
NCT02464761 · Sunnybrook Health Sciences Centre
2011-06 – 2017-09-07 · Vertebral Metastases
What this study did
NCT00002647 · Medical College of Wisconsin
started 1994-05 · Brain and Central Nervous System Tumors, Metastatic Cancer
What this study did
Phase 4 (9)
Age-Related Macular Degeneration
NCT04075136 · Wake Forest University Health Sciences
2023-03-30 – 2024-12 · Exudative Age Related Macular Degeneration
What this study did
NCT02120950 · Bayer
2014-05-29 – 2017-07-07 · Neovascular Macular Degeneration
What this study did
NCT01846273 · Novartis Pharmaceuticals
2013-08-07 – 2017-03-02 · Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
What this study did
NCT00473642 · Oklahoma State University Center for Health Sciences
2007-05 – 2010-04 · Age-Related Maculopathy, Choroidal Neovascularization
What this study did
NCT00331435 · Ophthalmic PDT Study Group
2006-06 – 2010-01 · Age Related Macular Degeneration
What this study did
NCT00680498 · Illinois Retina Associates
2007-02 – 2009-10 · Age-Related Macular Degeneration
What this study did
NCT00134667 · Eyetech Pharmaceuticals
2005-03 – 2008-10 · Age-Related Macular Degeneration
What this study did
NCT00135837 · Novartis
started 2003-06 · Age-Related Macular Degeneration
What this study did
Other / comorbidity
NCT00674323 · Novartis
2008-04 – 2009-05 · Polypoidal Choroidal Vasculopathy
What this study did
Early phase / not applicable (10)
Age-Related Macular Degeneration
NCT02457026 · Duke University
2016-01 – 2018-01 · Neovascular Age-related Macular Degeneration
What this study did
NCT01746875 · Norwegian University of Science and Technology
2014-02 – 2015-09 · Macular Degeneration, Retinal Detachment
What this study did
Other / comorbidity
NCT04429139 · Sun Yat-sen University
2011-02-01 – 2020-05-30 · Retinoblastoma
What this study did
NCT02872064 · University College, London
2013-01 – 2017-12 · Breast Neoplasms
What this study did
NCT03459144 · Sun Yat-sen University
2012-12-01 – 2015-07-30 · Polypoidal Choroidal Vasculopathy
What this study did
NCT01974622 · Manhattan Eye, Ear & Throat Hospital
2013-04 – 2015-06 · Retinal Vascular Disorders
What this study did
NCT01256580 · Massachusetts Eye and Ear Infirmary
2010-08 – 2013-09 · Choroidal Neovascularization, Myopia, Punctate Inner Choroidopathy (PIC), Multifocal Choroiditis, Ocular Histoplasmosis Syndrome, Central Serous Chorioretinopathy (CSC), Angioid Streaks, Trauma, or Hereditary Eye Diseases
What this study did
NCT01019668 · Shin Kong Wu Ho-Su Memorial Hospital
2008-11 – 2011-06 · Central Serous Chorioretinopathy
What this study did
NCT01360151 · Seoul St. Mary's Hospital
2011-02 – 2011-05 · Polypoidal Choroidal Vasculopathy
What this study did
NCT00471406 · Chonnam National University Hospital
— · Corneal Neovascularization
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Age-Related Macular Degeneration
NCT01482910 · Bayer
2011-12 – 2014-08 · Macular Degeneration
What this study did
Other / comorbidity
NCT01922102 · Novartis Pharmaceuticals
2013-09-11 – 2016-09-14 · Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
What this study did
NCT01217944 · Novartis Pharmaceuticals
2010-10 – 2012-08 · Pathological Myopia
What this study did
NCT00967850 · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
2008-04 – 2011-06 · Myopia, Choroidal Neovascularization
What this study did
Phase 2 (1)
Other / comorbidity
NCT00546936 · Barnes Retina Institute
2007-10 – 2010-04 · Presumed Ocular Histoplasmosis (POHS)
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Age-Related Macular Degeneration

Competitive landscape

This drug's own stage for Age-Related Macular Degeneration: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Verteporfin (Visudyne): this drugApprovedSmall moleculeBenzoporphyrin-derivative photosensitizer for photodynamic therapyPartial signal
NCT00436553: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 (Baseline and Month 12): Verteporfin SF + Ranibizumab — Baseline: 53.7 Letters (Standard Deviation 13.52); Month 12: 59 Letters (Standard Deviation 17.47); Change from baseline: 5.3 Letters (Standard Deviation 15.66) | Verteporfin RF + Ranibizumab — Baseline: 54.6 Letters (Standard Deviation 12.78); Month 12: 59 Letters (Standard Deviation 18.03); Change from baseline: 4.4 Letters (Standard Deviation 15.47) vs Ranibizumab Monotherapy — Baseline: 54.8 Letters (Standard Deviation 13.55); Month 12: 63 Letters (Standard Deviation 18.88); Change from baseline: 8.1 Letters (Standard Deviation 15.09) missed
NCT00121407: VIO trial, 24-month primary endpoint: 47% of verteporfin-PDT patients vs 53% of placebo patients lost ≥15 letters (not significant); source states n=384 vs task record's 364, but sponsor/design/QLT-era details match this trial (2:1 randomization, occult CNV, no classic component). missed
Aflibercept (Eylea)ApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Reliable signal
NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0)
NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42%
Aflibercept-Abzv (Enzeevu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-AReliable signal
NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97)
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Avacincaptad Pegol (Izervay)ApprovedRNA AptamerComplement C5Reliable signal
NCT04435366: 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165).
NCT02686658: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence (Baseline and 12 months): Zimura 2 mg [Part 1 & Part 2 Combined] 0.292 millimeters (mm) (Standard Error 0.077) | Zimura 4 mg [Part 2] 0.321 millimeters (mm) (Standard Error 0.074) vs Sham [Part 1 & Part 2 Combined] 0.402 millimeters (mm) (Standard Error 0.075) | Sham [Part 2] 0.444 millimeters (mm) (Standard Error 0.072)
Brolucizumab-DbllApprovedAntibody fragmentVEGF-AWeak signalNo reviewed efficacy summary in this indication
FaricimabApprovedMultispecific antibodyAngiopoietin-2 / VEGF-APartial signal
NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
Pegcetacoplan Ophthalmic (Syfovre)ApprovedPeptideComplement C3, Complement C3 / C3bReliable signal
NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218)
NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed
Ranibizumab (Lucentis)ApprovedAntibody fragmentVEGF-APartial signal
NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Axitinib Intravitreal Implant (OTX-TKI)Phase 3Small moleculeVEGF receptors + PDGF receptorsPartial signal
NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17).
BAT5906Phase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
CKD-701 (Lucenbies)Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%).
HLX04-OPhase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RC28-EPhase 3Protein / enzyme therapeuticVEGF-A / FGF-2 (dual blockade)Partial signal
NCT04270669: Mean BCVA improvement from baseline at week 48: 6.1 ± 8.3 letters (0.5 mg), 9.9 ± 10.7 letters (1.0 mg), 7.6 ± 9.4 letters (2.0 mg)
Surabgene LomparvovecPhase 3Gene therapy / editingVEGF-AWeak signal
NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0
Tabirafusp TedromerPhase 3Multispecific antibodyVEGF + IL-6Partial signal
NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28).
Tarcocimab TedromerPhase 3Monoclonal antibodyVEGF-APartial signal
NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76)
NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28).
VonaprumentPhase 3Antibody fragmentComplement C1qPartial signal
NCT04656561: GA lesion growth vs sham at 12 months: 6.2% reduction monthly (p=0.526), 1.3% every-other-month (p=0.896), 3.7% pooled (p=0.673); primary endpoint not statistically significant. missed
MW02Phase 2/3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
BI 1584862Phase 2——not yet gradedNo reviewed efficacy summary in this indication
BI 771716Phase 2Antibody fragment—Weak signalFeatured results are safety only in this race
Iptacopan (Fabhalta)Phase 2Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
ABBV-6628Phase 1/2Antibody fragmentComplement C5not yet gradedNo reviewed efficacy summary in this indication
SAR402663Phase 1/2Gene therapy / editingVEGFnot yet gradedNo reviewed efficacy summary in this indication
SAR446597Phase 1/2Gene therapy / editingComplement C1s + Factor Bbnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LazucirnonDiscontinuedSmall moleculeCCR3Partial signal
NCT04331730: Mean change in BCVA (ETDRS letters) from baseline to Week 36: AKST4290 800 mg + aflibercept +10.4 (SD 10.26, n=36), AKST4290 1600 mg + aflibercept +6.7 (SD 7.89, n=35), placebo + aflibercept +13.7 (SD 7.60, n=36); no between-group analysis posted (CT.gov posted results).

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Visudyne (Verteporfin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 1/2Recurrent Prostate CancerRecruiting
Est. primary completion 2027-07-31 · NCT03067051 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 1/2Prostate CancerRecruiting
Est. primary completion 2028-01 · NCT06807359 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 …Active not recruiting
Est. primary completion 2028-03-31 · NCT06381154 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Surgical ScarRecruiting
Est. primary completion 2028-08 · NCT07488988 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
Phase 1/2Malignant Solid NeoplasmRecruiting
Est. primary completion 2029-10-01 · NCT06306638 · CT.gov ↗
What to watch

See the full readout calendar ↗